Outcomes in COVID-19 quercetin studies
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Di Pierro (RCT) 86%
0.14 [0.01-2.72]
death
0/76
3/76
Improvement, RR [CI] Treatment Control Di Pierro (RCT) 67%
0.33 [0.01-7.74]
death
0/21
1/21
Tau2 = 0.00; I2 = 0.0%
Early treatment 79%
0.21 [0.02-1.82]
0/97
4/97
79% improvement Onal (RCT) -29%
1.29 [0.16-10.5]
death
1/49
6/380
CT1
Improvement, RR [CI] Treatment Control Zupanets (RCT) 29%
0.71 [0.32-1.58]
no recov.
9/99
13/101
Tau2 = 0.00; I2 = 0.0%
Late treatment 24%
0.76 [0.36-1.62]
10/148
19/481
24% improvement Arslan (RCT) 92%
0.08 [0.01-0.79]
cases
1/71
9/42
CT1
Improvement, RR [CI] Treatment Control Tau2 = 0.00; I2 = 0.0%
Prophylaxis 92%
0.08 [0.01-0.79]
1/71
9/42
92% improvement All studies 56%
0.44 [0.17-1.13]
11/316
32/620
56% improvement 5 quercetin COVID-19 studies c19quercetin.com Dec 3, 2021
1 CT: study uses combined treatment Tau2 = 0.29; I2 = 23.5%; Z = 1.70 Effect extraction pre-specified
Favors quercetin
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Di Pierro (RCT) 86%
0.14 [0.01-2.72]
0/76
3/76
Improvement, RR [CI] Treatment Control Di Pierro (RCT) 67%
0.33 [0.01-7.74]
0/21
1/21
Tau2 = 0.00; I2 = 0.0%
Early treatment 79%
0.21 [0.02-1.82]
0/97
4/97
79% improvement Onal (RCT) -29%
1.29 [0.16-10.5]
1/49
6/380
CT1
Improvement, RR [CI] Treatment Control Tau2 = 0.00; I2 = 0.0%
Late treatment -29%
1.29 [0.16-10.5]
1/49
6/380
-29% improvement All studies 46%
0.54 [0.12-2.40]
1/146
10/477
46% improvement 3 quercetin COVID-19 mortality results c19quercetin.com Dec 3, 2021
1 CT: study uses combined treatment Tau2 = 0.00; I2 = 0.0%; Z = 0.81 Favors quercetin
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Di Pierro (RCT) 94%
0.06 [0.00-1.00]
0/76
8/76
Improvement, RR [CI] Treatment Control Di Pierro (RCT) 67%
0.33 [0.01-7.74]
0/21
1/21
Tau2 = 0.00; I2 = 0.0%
Early treatment 87%
0.13 [0.02-1.05]
0/97
9/97
87% improvement Onal (RCT) 94%
0.06 [0.00-0.98]
0/49
14/380
CT1
Improvement, RR [CI] Treatment Control Tau2 = 0.00; I2 = 0.0%
Late treatment 94%
0.06 [0.00-0.98]
0/49
14/380
94% improvement All studies 90%
0.10 [0.02-0.52]
0/146
23/477
90% improvement 3 quercetin COVID-19 ICU results c19quercetin.com Dec 3, 2021
1 CT: study uses combined treatment Tau2 = 0.00; I2 = 0.0%; Z = 2.71 Favors quercetin
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Di Pierro (RCT) 68%
0.32 [0.14-0.70]
hosp.
7/76
22/76
Improvement, RR [CI] Treatment Control Di Pierro (RCT) 67%
0.33 [0.01-7.74]
hosp.
0/21
1/21
Tau2 = 0.00; I2 = 0.0%
Early treatment 68%
0.32 [0.15-0.69]
7/97
23/97
68% improvement All studies 68%
0.32 [0.15-0.69]
7/97
23/97
68% improvement 2 quercetin COVID-19 hospitalization results c19quercetin.com Dec 3, 2021
Tau2 = 0.00; I2 = 0.0%; Z = 2.93
Favors quercetin
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Di Pierro (RCT) 86%
0.14 [0.01-2.72]
death
0/76
3/76
Improvement, RR [CI] Treatment Control Di Pierro (RCT) 67%
0.33 [0.01-7.74]
death
0/21
1/21
Tau2 = 0.00; I2 = 0.0%
Early treatment 79%
0.21 [0.02-1.82]
0/97
4/97
79% improvement Onal (RCT) -29%
1.29 [0.16-10.5]
death
1/49
6/380
CT1
Improvement, RR [CI] Treatment Control Tau2 = 0.00; I2 = 0.0%
Late treatment -29%
1.29 [0.16-10.5]
1/49
6/380
-29% improvement All studies 46%
0.54 [0.12-2.40]
1/146
10/477
46% improvement 3 quercetin COVID-19 serious outcomes c19quercetin.com Dec 3, 2021
1 CT: study uses combined treatment Tau2 = 0.00; I2 = 0.0%; Z = 0.81 Effect extraction pre-specified
Favors quercetin
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Onal (RCT) 78%
0.22 [0.03-1.58]
no disch.
1/49
35/380
CT1
Improvement, RR [CI] Treatment Control Zupanets (RCT) 29%
0.71 [0.32-1.58]
no recov.
9/99
13/101
Tau2 = 0.09; I2 = 12.7%
Late treatment 43%
0.57 [0.23-1.38]
10/148
48/481
43% improvement All studies 43%
0.57 [0.23-1.38]
10/148
48/481
43% improvement 2 quercetin COVID-19 recovery results c19quercetin.com Dec 3, 2021
1 CT: study uses combined treatment Tau2 = 0.09; I2 = 12.7%; Z = 1.25 Favors quercetin
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Arslan (RCT) 92%
0.08 [0.01-0.79]
1/71
9/42
CT1
Improvement, RR [CI] Treatment Control Tau2 = 0.00; I2 = 0.0%
Prophylaxis 92%
0.08 [0.01-0.79]
1/71
9/42
92% improvement All studies 92%
0.08 [0.01-0.63]
1/71
9/42
92% improvement 1 quercetin COVID-19 case result c19quercetin.com Dec 3, 2021
1 CT: study uses combined treatment Tau2 = 0.00; I2 = 0.0%; Z = 2.40 Favors quercetin
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Di Pierro (RCT) 74%
0.26 [0.12-0.57]
viral+
5/21
19/21
Improvement, RR [CI] Treatment Control Tau2 = 0.00; I2 = 0.0%
Early treatment 74%
0.26 [0.12-0.57]
5/21
19/21
74% improvement All studies 74%
0.26 [0.12-0.57]
5/21
19/21
74% improvement 1 quercetin COVID-19 viral clearance result c19quercetin.com Dec 3, 2021
Tau2 = 0.00; I2 = 0.0%; Z = 3.37
Favors quercetin
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Di Pierro (RCT) 86%
0.14 [0.01-2.72]
death
0/76
3/76
Improvement, RR [CI] Treatment Control Di Pierro (RCT) 67%
0.33 [0.01-7.74]
death
0/21
1/21
Tau2 = 0.00; I2 = 0.0%
Early treatment 79%
0.21 [0.02-1.82]
0/97
4/97
79% improvement Onal (RCT) -29%
1.29 [0.16-10.5]
death
1/49
6/380
CT1
Improvement, RR [CI] Treatment Control Zupanets (RCT) 29%
0.71 [0.32-1.58]
no recov.
9/99
13/101
Tau2 = 0.00; I2 = 0.0%
Late treatment 24%
0.76 [0.36-1.62]
10/148
19/481
24% improvement Arslan (RCT) 92%
0.08 [0.01-0.79]
cases
1/71
9/42
CT1
Improvement, RR [CI] Treatment Control Tau2 = 0.00; I2 = 0.0%
Prophylaxis 92%
0.08 [0.01-0.79]
1/71
9/42
92% improvement All studies 56%
0.44 [0.17-1.13]
11/316
32/620
56% improvement 5 quercetin COVID-19 Randomized Controlled Trials c19quercetin.com Dec 3, 2021
1 CT: study uses combined treatment Tau2 = 0.29; I2 = 23.5%; Z = 1.70 Effect extraction pre-specified
Favors quercetin
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Di Pierro (RCT) 86%
0.14 [0.01-2.72]
0/76
3/76
Improvement, RR [CI] Treatment Control Di Pierro (RCT) 67%
0.33 [0.01-7.74]
0/21
1/21
Tau2 = 0.00; I2 = 0.0%
Early treatment 79%
0.21 [0.02-1.82]
0/97
4/97
79% improvement Onal (RCT) -29%
1.29 [0.16-10.5]
1/49
6/380
CT1
Improvement, RR [CI] Treatment Control Tau2 = 0.00; I2 = 0.0%
Late treatment -29%
1.29 [0.16-10.5]
1/49
6/380
-29% improvement All studies 46%
0.54 [0.12-2.40]
1/146
10/477
46% improvement 3 quercetin COVID-19 RCT mortality results c19quercetin.com Dec 3, 2021
1 CT: study uses combined treatment Tau2 = 0.00; I2 = 0.0%; Z = 0.81 Favors quercetin
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Di Pierro (RCT) 86%
0.14 [0.01-2.72]
death
0/76
3/76
Improvement, RR [CI] Treatment Control Di Pierro (RCT) 67%
0.33 [0.01-7.74]
death
0/21
1/21
Tau2 = 0.00; I2 = 0.0%
Early treatment 79%
0.21 [0.02-1.82]
0/97
4/97
79% improvement Onal (RCT) -29%
1.29 [0.16-10.5]
death
1/49
6/380
CT1
Improvement, RR [CI] Treatment Control Zupanets (RCT) 29%
0.71 [0.32-1.58]
no recov.
9/99
13/101
Tau2 = 0.00; I2 = 0.0%
Late treatment 24%
0.76 [0.36-1.62]
10/148
19/481
24% improvement All studies 34%
0.66 [0.33-1.35]
10/245
23/578
34% improvement 4 quercetin COVID-19 peer reviewed trials c19quercetin.com Dec 3, 2021
1 CT: study uses combined treatment Tau2 = 0.00; I2 = 0.0%; Z = 1.13 Effect extraction pre-specified
Favors quercetin
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Di Pierro (RCT) 86%
0.14 [0.01-2.72]
death
0/76
3/76
Improvement, RR [CI] Treatment Control Di Pierro (RCT) 94%
0.06 [0.00-1.00]
ICU
0/76
8/76
Di Pierro (RCT) 68%
0.32 [0.14-0.70]
hosp.
7/76
22/76
Di Pierro (RCT) 67%
0.33 [0.01-7.74]
death
0/21
1/21
Di Pierro (RCT) 67%
0.33 [0.01-7.74]
ICU
0/21
1/21
Di Pierro (RCT) 67%
0.33 [0.01-7.74]
hosp.
0/21
1/21
Di Pierro (RCT) 74%
0.26 [0.12-0.57]
viral+
5/21
19/21
Di Pierro (RCT) 89%
0.11 [0.01-1.94]
viral+
0/21
4/21
Onal (RCT) -29%
1.29 [0.16-10.5]
death
1/49
6/380
CT1
Onal (RCT) 94%
0.06 [0.00-0.98]
ICU
0/49
14/380
CT1
Onal (RCT) 78%
0.22 [0.03-1.58]
no disch.
1/49
35/380
CT1
Zupanets (RCT) 29%
0.71 [0.32-1.58]
no recov.
9/99
13/101
Zupanets (RCT) 18%
0.82 [0.68-0.98]
recov. time
99 (n)
101 (n)
Arslan (RCT) 92%
0.08 [0.01-0.79]
cases
1/71
9/42
CT1
quercetin COVID-19 outcomes c19quercetin.com Dec 3, 2021
Favors quercetin
Favors control
Please send us corrections, updates, or comments.
Vaccines and treatments are both extremely valuable and complementary. All
practical, effective, and safe means should be used. Elimination of COVID-19
is a race against viral evolution. No treatment, vaccine, or intervention is
100% available and effective for all current and future variants. Denying the
efficacy of any method increases the risk of COVID-19 becoming endemic; and
increases mortality, morbidity, and collateral damage. We do not provide
medical advice. Before taking any medication, consult a qualified physician
who can provide personalized advice and details of risks and benefits based
on your medical history and situation. Treatment protocols for physicians are
available from the FLCCC .
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.
Submit
